The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Ibuprofen More Likely to Raise BP than Naproxen or Celecoxib

Ibuprofen More Likely to Raise BP than Naproxen or Celecoxib

September 12, 2017 • By Anne Harding

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Ibuprofen boosts blood pressure (BP) more than naproxen or celecoxib in patients who take non-steroidal anti-inflammatory drugs (NSAIDs) to treat arthritis, according to a new substudy from the PRECISION trial.

You Might Also Like
  • Celecoxib & Cardiovascular Death: NSAID Safety Under Review
  • Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed
  • Celecoxib Is a Safe Treatment for Arthritis

“These drugs are different with regard to BP, and ibuprofen is the worst,” Dr. Frank Ruschitzka of University Hospital Zurich in Switzerland, the study’s first author, tells Reuters Health.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In 2015, the U.S. Food and Drug Administration strengthened its warning on the cardiovascular risks of over-the-counter NSAIDs and cyclooxygenase 2 (COX-2) inhibitors, Dr. Ruschitzka and his team note in their Aug. 28 online report in the European Heart Journal.1 Clinicians face difficult decisions on how to treat patients who take NSAIDs regularly to treat arthritis, they add, many of whom also have hypertension.

The PRECISION randomized trial, funded by celecoxib maker Pfizer and mandated by the FDA, compared the three drugs in patients with arthritis who either had cardiovascular disease or were at increased risk. Published in the New England Journal of Medicine in 2016, PRECISION showed that celecoxib’s cardiovascular safety was non-inferior to that of naproxen or ibuprofen.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the new PRECISION prespecified substudy, 444 arthritis patients underwent 24-hour ambulatory BP monitoring at baseline and after four months on celecoxib (100z–200 mg twice daily), ibuprofen (600–800 mg three times daily) or naproxen (375–500 mg twice daily). Mean baseline BP was 125/75 mmHg and very similar among the groups.

Mean 24-hour systolic BP increased by 3.7 mmHg in ibuprofen users and by 1.6 mmHg in naproxen users, and it decreased by 0.3 mmHg in celecoxib users. Among people with normal baseline BP, hypertension developed in significantly more ibuprofen users (23.2%) than users of naproxen (19.0%) or celecoxib (10.3%).

COX-2 inhibitors don’t carry the risk of gastrointestinal side effects associated with traditional NSAIDs, but an increased risk of heart failure associated with Vioxx (rofecoxib) led to concerns about its cardiovascular effects. Merck withdrew Vioxx from the market in 2004. Research done at that time found no evidence for increased cardiovascular risk with celecoxib, Dr. William White of UConn Health in Farmington, Conn., an expert on NSAIDs’ cardiovascular effects, tells Reuters Health.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“The ambulatory [BP] study, which is in a very small percentage of the patients in PRECISION, the findings were completely predictable based on all of the other studies that have been done,” Dr. White says.

Nevertheless, the differences are likely to be news for young doctors, who may not be familiar with that research, he adds.

Pages: 1 2 | Single Page

Filed Under: Analgesics, Drug Updates Tagged With: Arthritis, blood pressure, celecoxib, Ibuprofen, naproxen, Nonsteroidal anti-inflammatory drugs (NSAIDs), NSAIDs, Pain

You Might Also Like:
  • Celecoxib & Cardiovascular Death: NSAID Safety Under Review
  • Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed
  • Celecoxib Is a Safe Treatment for Arthritis
  • Study Examines Why Patients Exceed Recommended Doses of Ibuprofen & NSAIDs

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.